# ClinicalTrials.gov record NCT02693119

> PeptideScanner retained ClinicalTrials.gov record NCT02693119 at 2026-07-30T19:56:31.565Z. Its registry update date was 2021-11-30, and PeptideScanner's reviewed identity mapping was elamipretide.

- Evidence object: `story:clinicaltrials-gov-nct02693119-elamipretide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-11-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02693119-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02693119-elamipretide-v1.json
- Content SHA-256: `03258ee947f0aabc82c4d4b7f4c78125aba467fbbd83beb23fd485449a3f2cb6`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02693119 ([`ctg-observation-nct02693119-2021-11-30-e6845fd49543`](#source-ctg-observation-nct02693119-2021-11-30-e6845fd49543))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02693119 at 2026-07-30T19:56:31.565Z. Its registry update date was 2021-11-30, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct02693119-2021-11-30-e6845fd49543`](#source-ctg-observation-nct02693119-2021-11-30-e6845fd49543))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02693119 at 2026-07-30T19:56:31.565Z. Its registry update date was 2021-11-30, and PeptideScanner's reviewed identity mapping was elamipretide. ([`ctg-observation-nct02693119-2021-11-30-e6845fd49543`](#source-ctg-observation-nct02693119-2021-11-30-e6845fd49543))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02693119-2021-11-30-e6845fd49543`](#source-ctg-observation-nct02693119-2021-11-30-e6845fd49543))

## Sources

<a id="source-ctg-observation-nct02693119-2021-11-30-e6845fd49543"></a>
- **ClinicalTrials.gov record NCT02693119 · retained source version 2021-11-30:e6845fd4954350c08ae8b4d48e1bf0b16fc5add78a67eb673d75cbdee4d7e2bb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02693119) (`ctg-observation-nct02693119-2021-11-30-e6845fd49543`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02693119." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02693119-elamipretide-v1.json SHA-256: 03258ee947f0aabc82c4d4b7f4c78125aba467fbbd83beb23fd485449a3f2cb6.